TheBullLady
Well-known member
NEW ANTIBIOTIC PRODUCT
Pfizer is marketing a new product for treatment of Bovine Respiratory Disease complex, ExcedeTM , which is a ceftiofur formulation. Excede differs from other ceftiofur products in that therapeutic blood levels are maintained for 7 days. Also, administration is subcutaneous in the middle third of the ear, similar to the location for growth implants. (The product can be administered along with implants.) Because of this location, there is no slaughter withdrawal time. A special needle with a 45 degree bevel is recommended for proper administration, instead of standard needles with 21 to 28 degree bevels, to reduce potential hazards of penetrating arteries in the ear. (Pfizer Animal Health website)
Pfizer is marketing a new product for treatment of Bovine Respiratory Disease complex, ExcedeTM , which is a ceftiofur formulation. Excede differs from other ceftiofur products in that therapeutic blood levels are maintained for 7 days. Also, administration is subcutaneous in the middle third of the ear, similar to the location for growth implants. (The product can be administered along with implants.) Because of this location, there is no slaughter withdrawal time. A special needle with a 45 degree bevel is recommended for proper administration, instead of standard needles with 21 to 28 degree bevels, to reduce potential hazards of penetrating arteries in the ear. (Pfizer Animal Health website)